Michael Cherny
Stock Analyst at Leerink Partners
(5.00)
# 8
Out of 4,784 analysts
137
Total ratings
55.21%
Success rate
107.55%
Average return
Main Sectors:
Stocks Rated by Michael Cherny
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEDP Medpace Holdings | Initiates: Market Perform | $330 | $313.43 | +5.29% | 1 | Mar 24, 2025 | |
| HIMS Hims & Hers Health | Maintains: Market Perform | $24 → $40 | $29.50 | +35.59% | 10 | Feb 25, 2025 | |
| CVS CVS Health | Upgrades: Outperform | $55 → $75 | $66.75 | +12.37% | 11 | Feb 13, 2025 | |
| PGNY Progyny | Maintains: Buy | $21 → $25 | $21.76 | +14.89% | 10 | Feb 11, 2025 | |
| DOCS Doximity | Upgrades: Outperform | $60 → $90 | $57.99 | +55.20% | 2 | Feb 7, 2025 | |
| ACCD Accolade | Downgrades: Market Perform | n/a | $6.99 | - | 8 | Jan 8, 2025 | |
| MCK McKesson | Maintains: Buy | $680 → $650 | $666.00 | -2.40% | 11 | Jan 6, 2025 | |
| ALGN Align Technology | Upgrades: Outperform | $235 → $280 | $159.39 | +75.67% | 2 | Jan 6, 2025 | |
| DGX Quest Diagnostics | Upgrades: Outperform | $135 → $174 | $166.91 | +4.25% | 2 | Jan 6, 2025 | |
| CAH Cardinal Health | Upgrades: Buy | $132 → $145 | $136.26 | +6.41% | 10 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $69 → $84 | $69.02 | +21.70% | 2 | Jan 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $29 → $31 | $31.24 | +0.37% | 24 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $260 → $248 | $177.97 | +39.35% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $270 → $255 | $178.43 | +42.91% | 3 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $15.00 | - | 8 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | $16 → $23 | $16.98 | +35.49% | 10 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $277 → $275 | $273.84 | +0.42% | 3 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.53 | +1,533.99% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $23 → $22 | $11.16 | +97.13% | 2 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $260 | $229.10 | +13.49% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $23 | $19.15 | +17.52% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $8 | $4.52 | +76.99% | 5 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $19 | $9.81 | +93.68% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $17 | $8.10 | +110.01% | 1 | Feb 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $113 → $53 | $12.38 | +324.07% | 2 | Jan 5, 2022 |
Medpace Holdings
Mar 24, 2025
Initiates: Market Perform
Price Target: $330
Current: $313.43
Upside: +5.29%
Hims & Hers Health
Feb 25, 2025
Maintains: Market Perform
Price Target: $24 → $40
Current: $29.50
Upside: +35.59%
CVS Health
Feb 13, 2025
Upgrades: Outperform
Price Target: $55 → $75
Current: $66.75
Upside: +12.37%
Progyny
Feb 11, 2025
Maintains: Buy
Price Target: $21 → $25
Current: $21.76
Upside: +14.89%
Doximity
Feb 7, 2025
Upgrades: Outperform
Price Target: $60 → $90
Current: $57.99
Upside: +55.20%
Accolade
Jan 8, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $6.99
Upside: -
McKesson
Jan 6, 2025
Maintains: Buy
Price Target: $680 → $650
Current: $666.00
Upside: -2.40%
Align Technology
Jan 6, 2025
Upgrades: Outperform
Price Target: $235 → $280
Current: $159.39
Upside: +75.67%
Quest Diagnostics
Jan 6, 2025
Upgrades: Outperform
Price Target: $135 → $174
Current: $166.91
Upside: +4.25%
Cardinal Health
Jan 6, 2025
Upgrades: Buy
Price Target: $132 → $145
Current: $136.26
Upside: +6.41%
Jan 6, 2025
Upgrades: Buy
Price Target: $69 → $84
Current: $69.02
Upside: +21.70%
Dec 11, 2024
Downgrades: Market Perform
Price Target: $29 → $31
Current: $31.24
Upside: +0.37%
Nov 19, 2024
Reiterates: Outperform
Price Target: $260 → $248
Current: $177.97
Upside: +39.35%
Nov 19, 2024
Reiterates: Outperform
Price Target: $270 → $255
Current: $178.43
Upside: +42.91%
Nov 7, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $15.00
Upside: -
Oct 31, 2024
Upgrades: Market Perform
Price Target: $16 → $23
Current: $16.98
Upside: +35.49%
Oct 7, 2024
Maintains: Outperform
Price Target: $277 → $275
Current: $273.84
Upside: +0.42%
Apr 22, 2024
Initiates: Outperform
Price Target: $25
Current: $1.53
Upside: +1,533.99%
Mar 18, 2024
Maintains: Market Perform
Price Target: $23 → $22
Current: $11.16
Upside: +97.13%
Feb 26, 2024
Initiates: Outperform
Price Target: $260
Current: $229.10
Upside: +13.49%
Feb 26, 2024
Initiates: Market Perform
Price Target: $23
Current: $19.15
Upside: +17.52%
Feb 26, 2024
Initiates: Outperform
Price Target: $8
Current: $4.52
Upside: +76.99%
Feb 26, 2024
Initiates: Market Perform
Price Target: $19
Current: $9.81
Upside: +93.68%
Feb 26, 2024
Initiates: Market Perform
Price Target: $17
Current: $8.10
Upside: +110.01%
Jan 5, 2022
Downgrades: Underperform
Price Target: $113 → $53
Current: $12.38
Upside: +324.07%